DCM
DCPH

DAFNA Capital Management’s Deciphera Pharmaceuticals, Inc. Common Stock DCPH Stock Holding History

DAFNA Capital Management’s Portfolio DCPH Stock Details DCPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-9,619
Closed -$218K – 81
2017
Q4 		$218K Sell
9,619
-10,381
-52% -$203K 0.12% 67
2017
Q3 		$380K Buy
+20,000
New +$366K 0.24% 60

Other funds holding DCPH

NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

DAFNA Capital Management's DCPH Position: Q1 2018 in Review

DAFNA Capital Management sold out of Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) in Q1 2018, closing a stake of 9,619 shares — an estimated $218K sold.

DAFNA Capital Management first reported a position in DCPH in Q3 2017 and held it in 2 quarters. The position peaked at $380K in Q3 2017. 55 funds tracked by Wall St. Rank hold DCPH as of Q1 2018.

  • DAFNA Capital Management reported no remaining Deciphera Pharmaceuticals, Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
  • DAFNA Capital Management sold 9,619 Deciphera Pharmaceuticals, Inc. Common Stock shares in Q1 2018, an estimated $218K.
  • DAFNA Capital Management first reported a position in Deciphera Pharmaceuticals, Inc. Common Stock in Q3 2017 and held it in 2 quarters.
  • DAFNA Capital Management's Deciphera Pharmaceuticals, Inc. Common Stock position peaked at $380K in Q3 2017.
  • 55 funds tracked by Wall St. Rank held Deciphera Pharmaceuticals, Inc. Common Stock as of Q1 2018.

Based on DAFNA Capital Management's 13F filing for Q1 2018, filed 15 May 2018.